Kurve Therapeutics Stock (KUTH)

Kurve Therapeutics engages in the development of treatments for neurodegenerative diseases. Its drug delivery technology is designed to target the most difficult part of the treatment process — getting medication through the blood-brain barrier and into the brain. Through the development of their patented Controlled Particle Dispersion technology, Kurve Therapeutics aims to reshape the landscape of cognitive aging, neurodegenerative diseases, and related disorders. Its next-generation technology has been shown to deliver up to 30x more disease-modifying medication directly to the brain than infusions in several Phase II studies. This allows for significant dose flexibility away from toxic doses for a safer, more efficacious therapy. While traditional treatment options continually prove ineffective at stopping neurodegenerative disease progression and often lead to toxicity or continued decline, Kurve is developing a new disease-modifying approach.